Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas.

Yang SX, Kummar S, Steinberg SM, Murgo AJ, Gutierrez M, Rubinstein L, Nguyen D, Kaur G, Chen AP, Giranda VL, Tomaszewski JE, Doroshow JH; National Cancer Institute Phase 0 Working Group..

Cancer Biol Ther. 2009 Nov;8(21):2004-9. Epub 2009 Nov 25.

PMID:
19823047
3.

Modeling pharmacodynamic response to the poly(ADP-Ribose) polymerase inhibitor ABT-888 in human peripheral blood mononuclear cells.

Ji J, Kinders RJ, Zhang Y, Rubinstein L, Kummar S, Parchment RE, Tomaszewski JE, Doroshow JH.

PLoS One. 2011;6(10):e26152. doi: 10.1371/journal.pone.0026152. Epub 2011 Oct 10.

4.

Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts.

Kinders RJ, Hollingshead M, Khin S, Rubinstein L, Tomaszewski JE, Doroshow JH, Parchment RE; National Cancer Institute Phase 0 Clinical Trials Team..

Clin Cancer Res. 2008 Nov 1;14(21):6877-85. doi: 10.1158/1078-0432.CCR-08-0214.

5.

Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies.

Kummar S, Kinders R, Gutierrez ME, Rubinstein L, Parchment RE, Phillips LR, Ji J, Monks A, Low JA, Chen A, Murgo AJ, Collins J, Steinberg SM, Eliopoulos H, Giranda VL, Gordon G, Helman L, Wiltrout R, Tomaszewski JE, Doroshow JH.

J Clin Oncol. 2009 Jun 1;27(16):2705-11. doi: 10.1200/JCO.2008.19.7681. Epub 2009 Apr 13.

6.

The poly(ADP-Ribose) polymerase inhibitor ABT-888 reduces radiation-induced nuclear EGFR and augments head and neck tumor response to radiotherapy.

Nowsheen S, Bonner JA, Yang ES.

Radiother Oncol. 2011 Jun;99(3):331-8. doi: 10.1016/j.radonc.2011.05.084. Epub 2011 Jun 28.

7.

An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors.

Liu X, Palma J, Kinders R, Shi Y, Donawho C, Ellis PA, Rodriguez LE, Colon-Lopez M, Saltarelli M, LeBlond D, Lin CT, Frost DJ, Luo Y, Giranda VL.

Anal Biochem. 2008 Oct 15;381(2):240-7. doi: 10.1016/j.ab.2008.07.007. Epub 2008 Jul 16.

PMID:
18674509
8.

Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas.

Kummar S, Chen A, Ji J, Zhang Y, Reid JM, Ames M, Jia L, Weil M, Speranza G, Murgo AJ, Kinders R, Wang L, Parchment RE, Carter J, Stotler H, Rubinstein L, Hollingshead M, Melillo G, Pommier Y, Bonner W, Tomaszewski JE, Doroshow JH.

Cancer Res. 2011 Sep 1;71(17):5626-34. doi: 10.1158/0008-5472.CAN-11-1227. Epub 2011 Jul 27.

9.

MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers.

Vilar E, Bartnik CM, Stenzel SL, Raskin L, Ahn J, Moreno V, Mukherjee B, Iniesta MD, Morgan MA, Rennert G, Gruber SB.

Cancer Res. 2011 Apr 1;71(7):2632-42. doi: 10.1158/0008-5472.CAN-10-1120. Epub 2011 Feb 7.

10.

Synergistic cytotoxicity of the poly (ADP-ribose) polymerase inhibitor ABT-888 and temozolomide in dual-drug targeted magnetic nanoparticles.

Muñoz-Gámez JA, López Viota J, Barrientos A, Carazo Á, Sanjuán-Nuñez L, Quiles-Perez R, Muñoz-de-Rueda P, Delgado Á, Ruiz-Extremera Á, Salmerón J.

Liver Int. 2015 Apr;35(4):1430-41. doi: 10.1111/liv.12586. Epub 2014 Jun 3.

PMID:
24821649
11.

Poly(ADP-ribose) polymerase inhibitors combined with external beam and radioimmunotherapy to treat aggressive lymphoma.

Schaefer NG, James E, Wahl RL.

Nucl Med Commun. 2011 Nov;32(11):1046-51. doi: 10.1097/MNM.0b013e32834a369b.

12.

ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models.

Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ, Bontcheva-Diaz VD, Cox BF, DeWeese TL, Dillehay LE, Ferguson DC, Ghoreishi-Haack NS, Grimm DR, Guan R, Han EK, Holley-Shanks RR, Hristov B, Idler KB, Jarvis K, Johnson EF, Kleinberg LR, Klinghofer V, Lasko LM, Liu X, Marsh KC, McGonigal TP, Meulbroek JA, Olson AM, Palma JP, Rodriguez LE, Shi Y, Stavropoulos JA, Tsurutani AC, Zhu GD, Rosenberg SH, Giranda VL, Frost DJ.

Clin Cancer Res. 2007 May 1;13(9):2728-37.

13.

Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models.

Albert JM, Cao C, Kim KW, Willey CD, Geng L, Xiao D, Wang H, Sandler A, Johnson DH, Colevas AD, Low J, Rothenberg ML, Lu B.

Clin Cancer Res. 2007 May 15;13(10):3033-42.

14.

PARP inhibitor ABT-888 affects response of MDA-MB-231 cells to doxorubicin treatment, targeting Snail expression.

Mariano G, Ricciardi MR, Trisciuoglio D, Zampieri M, Ciccarone F, Guastafierro T, Calabrese R, Valentini E, Tafuri A, Del Bufalo D, Caiafa P, Reale A.

Oncotarget. 2015 Jun 20;6(17):15008-21.

15.

Doxorubicin-induced suppression of poly(ADP-ribose) polymerase-1 (PARP-1) activity and expression and its implication for PARP inhibitors in clinical trials.

Zaremba T, Thomas H, Cole M, Plummer ER, Curtin NJ.

Cancer Chemother Pharmacol. 2010 Sep;66(4):807-12. doi: 10.1007/s00280-010-1359-0. Epub 2010 May 21.

PMID:
20490796
16.

A key role for poly(ADP-ribose) polymerase-1 activity during human dendritic cell maturation.

Aldinucci A, Gerlini G, Fossati S, Cipriani G, Ballerini C, Biagioli T, Pimpinelli N, Borgognoni L, Massacesi L, Moroni F, Chiarugi A.

J Immunol. 2007 Jul 1;179(1):305-12.

17.

[Inhibitory effect of 5-aminoisoquinolinone on PARP activity in colon carcinoma cell line HT-29].

Hao LX, Wang YL, Cai L, Li YY.

Ai Zheng. 2007 Jun;26(6):566-71. Chinese.

PMID:
17562258
18.

PARP inhibitors attenuate chemotherapy-induced painful neuropathy.

Brederson JD, Joshi SK, Browman KE, Mikusa J, Zhong C, Gauvin D, Liu X, Shi Y, Penning TD, Shoemaker AR, Giranda VL.

J Peripher Nerv Syst. 2012 Sep;17(3):324-30. doi: 10.1111/j.1529-8027.2012.00413.x.

PMID:
22971094
20.

Roles of inhibitors of poly(ADP-ribose) polymerase in protecting rat RINm5F cell line against free fatty acid-induced apoptosis.

Mao X, Wang S, Pan Y, He B, Chen J, Jiang H, Zeng Q, Xu X.

Exp Clin Endocrinol Diabetes. 2009 Jun;117(6):274-82. doi: 10.1055/s-0029-1202794. Epub 2009 Jun 9.

PMID:
19513971

Supplemental Content

Support Center